Structure Therapeutics(NASDAQ) GPCR

Structure Therapeutics develops easy-to-take pills for people living with weight and heart health problems. These oral medicines aim to replace painful injections that many patients currently use to manage their conditions. The company focuses on turning complex protein-based treatments into simple daily tablets.

Pills for Weight and Wellness

• Metabolic Candidates: Oral small molecule treatments like aleniglipron designed to help patients lose weight and manage blood sugar levels.
• Amylin Agonists: Pill-based therapies including ACCG-2671 and ACCG-3535 that signal the brain to feel full and slow digestion.
• Respiratory and Cardiovascular: Experimental treatments such as LTSE-2578 designed to block scarring in the lungs and improve heart function.

Strategic Moves and Partnerships

• Signed a license agreement with Genentech and Roche in December 2025, receiving a $100 million payment for specific drug patents.
• Partnered with Schrodinger to use advanced computer simulations for finding and perfecting new drug molecules.
• Completed enrollment for the ACCESS and ACCESS II clinical studies in February 2025 to test weight-loss pill effectiveness.
• Transitioned from a private entity formerly known as ShouTi Inc. to a public company listed on the Nasdaq in February 2023.

What Makes the Company Unique

The company uses 25 years of research to build three-dimensional maps of cell receptors to find where medicine can best attach. This computer-aided design allows them to manufacture 6,000 tons of medicine per year, enough to treat over 120 million people.

The Recent Financial Record

• Net income reached $33 million in Q4 2025, up 190.5% from the previous year.
• Operating income rose to $24 million in Q4 2025, an increase of 151% year-over-year.
• Market capitalization grew to $4.1 billion in Q4 2025, up 165% from Q4 2024.
• Free cash flow was negative $65.9 million in Q4 2025, down 80.7% from the prior year as research spending continued.

Evolution and Future Outlook

Structure Therapeutics has moved from a research startup to a clinical-stage company with a broad pipeline of oral metabolic drugs. By securing major industry partnerships and advancing multiple candidates into late-stage trials, the firm has transitioned into a significant player in the obesity treatment market.